logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Drugs

Results

Drugs

September 2021

Levodopa, carbidopa monohydrate and entacapone intestinal gel for severe motor fluctuations in advanced Parkinson’s Disease

Levodopa, carbidopa monohydrate and entacapone intestinal gel (LECIG, TRICEL, Lecigon) is in development to treat severe motor fluctuations in advanced Parkinson’s disease (PD). PD is a progressive neurological disease caused by a loss of nerve cells in a particular part of the brain that results in decreased levels of the chemical messenger dopamine. This results …

Drugs

September 2021

Ciltacabtagene autoleucel for relapsed and refractory multiple myeloma

Ciltacabtagene autoleucel is in clinical development for the treatment of adults with relapsed and lenalidomide-refractory multiple myeloma (MM). MM is a rare, incurable cancer of the plasma cells in the bone marrow. Abnormal plasma cells interfere with the production of red and white blood cells as well as platelets, causing symptoms such as bone pain …

Drugs

September 2021

CTX001 for severe sickle cell disease

CTX001 is in clinical development for patients with severe sickle cell disease (SCD). SCD is a group of inherited disorders where the red blood cells become hard and sticky and look like a C-shaped farm tools called a “sickle” and these sickle red blood cells die early. Individuals with SCD have inherited the gene for …

Drugs

September 2021

Pembrolizumab in combination with olaparib for treatment of metastatic squamous non-small cell lung cancer

Pembrolizumab in combination with olaparib is in clinical development for the treatment of metastatic squamous non-small cell lung cancer (NSCLC). NSCLC makes up the majority of lung cancers in the UK and squamous NSCLC is where the cancer begins in the flat cells that cover the surface of the airway. Metastatic (advanced) NSCLC refers to …

Drugs

September 2021

Bimekizumab for non-radiographic axial spondyloarthritis

Bimekizumab is in clinical development for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA). This condition affects patients predominantly in the spine and other areas of the body and is caused by inflammation. This inflammation can lead to back pain, fatigue and in serious cases, to severe disability as the bones of the spine …

Drugs

September 2021

Nivolumab in combination with chemoradiotherapy for squamous cell head and neck cancer

Nivolumab in combination with cisplatin-based chemoradiotherapy (cisplatin-RT) is currently in development for the adjuvant treatment of high-risk patients with metastatic squamous cell carcinoma of the head and neck (HNSCC) following surgery to remove the cancer. HNSCC is a cancer of the mouth, nose or throat that develops in the squamous cells found in the outer …

Drugs

September 2021

CTX001 for transfusion-dependent beta (β)-thalassaemia

CTX001 is under clinical development for the treatment of patients with beta-thalassaemia who require blood transfusions. Thalassaemia is a commonly inherited blood disorder resulting from an abnormality in one of the genes that affects the production of haemoglobin, a protein in red blood cells that carries oxygen throughout the body. Beta-thalassaemia is a subtype caused …

Drugs

September 2021

Talazoparib in addition to enzalutamide for metastatic castration-resistant prostate cancer

Talazoparib in addition to enzalutamide is in clinical development for patients with metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is the most common type of cancer in men in the UK. The cancer is called advanced (metastatic) prostate cancer when the cancer cells have spread to other parts of the body like bones, lymph nodes …

Drugs

September 2021

Dulaglutide for Type 2 diabetes

Dulaglutide is in clinical development for the treatment of children and adolescents with type 2 diabetes mellitus (T2DM). T2DM is a lifelong condition that develops when the body becomes resistant to, or does not produce enough, insulin – a hormone produced in the pancreas. Insulin is needed for glycaemic control (controlling the amount of sugar …

Drugs

September 2021

Zilucoplan for treating generalised myasthenia gravis

Zilucoplan is currently in clinical development for adult patients with class II-IV generalized Myasthenia Gravis (gMG) who are Acetylcholine Receptor (AChR) antibody positive. Myasthenia gravis (MG) is a rare and chronic autoimmune disease. MG results from an abnormal immune reaction in which the body’s natural immune defences (i.e., antibodies) inappropriately attack certain receptors in muscles, …

Get Alerts